<DOC>
	<DOCNO>NCT00757731</DOCNO>
	<brief_summary>Investigation long-term ( 12 month ) efficacy safety milnacipran use treatment fibromyalgia syndrome .</brief_summary>
	<brief_title>FMS European Long-Term Study</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Fibromyalgia</mesh_term>
	<mesh_term>Myofascial Pain Syndromes</mesh_term>
	<mesh_term>Milnacipran</mesh_term>
	<criteria>patient complete 3month F02207 GE 302 study patient diagnosis fibromyalgia accord 1990 ACR criterion entry F02207 GE 302 study know hypersensitivity milnacipran major depressive episode significant risk suicide generalise anxiety disorder substance abuse clinically significant cardiac disease pulmonary dysfunction active liver disease renal impairment autoimmune disease current systemic infection epileptic active cancer severe sleep apnoea active peptic ulcer inflammatory bowel disease unstable endocrine disease ( men ) prostatic enlargement genitourinary disorder ( woman ) pregnancy breastfeed</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>71 Years</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>